8-aminoguanosine has been researched along with Disease-Models--Animal* in 2 studies
2 other study(ies) available for 8-aminoguanosine and Disease-Models--Animal
Article | Year |
---|---|
A rat model of purine nucleoside phosphorylase deficiency.
Purine nucleoside phosphorylase (NP; EC 2.4.2.1) deficiency is associated with selective T-cell dysfunction and normal B-cell immunity. In order to create an in vivo model of this immune deficiency, we administered 8-aminoguanosine to rats. This water-soluble nucleoside was rapidly converted by NP to the more potent inhibitor 8-aminoguanine, which has a Ki of 0.19 microM. The accumulation of inosine in plasma showed that administration of 8-aminoguanosine was effectively inhibiting NP activity. The administration of 8-aminoguanosine with deoxyguanosine produced increased levels of dGTP only in thymus cells, and increased levels of GTP in cells from thymus, spleen and lymph node and in red cells. This correlated with assays of deoxyguanosine kinase, which showed significantly higher activity in thymus cells than in cells from spleen and lymph node. The intraperitoneal injection of 8-aminoguanosine alone or with deoxyguanosine for 8 consecutive days caused significant decreases in the number of thymus cells (P less than 0.001) and in lymph node and spleen lymphocytes (P less than 0.01). These data showed that the administration of 8-aminoguanosine to rats provided an animal model of NP deficiency that will allow studies of the specific regulation of T-cell function. Topics: Animals; Deoxyguanine Nucleotides; Deoxyguanosine; Disease Models, Animal; Erythrocytes; Female; Guanosine; Guanosine Triphosphate; Lymphoid Tissue; Male; Pentosyltransferases; Phosphotransferases; Phosphotransferases (Alcohol Group Acceptor); Purine-Nucleoside Phosphorylase; Rats; Rats, Inbred Lew | 1986 |
A canine model of induced purine nucleoside phosphorylase deficiency.
Purine nucleoside phosphorylase (NP EC 2.4.2.1) deficiency in man is associated with selective T cell dysfunction and normal B cell immunity. To create an in-vivo model of this immune deficiency, we administered 8-aminoguanosine to dogs. This water soluble nucleoside was rapidly converted by NP to the more potent product inhibitor 8-aminoguanine, which had a Ki of 0.52 microM. The accumulation of inosine and exogenous deoxyguanosine in plasma provided evidence that administration of 8-aminoguanosine was effectively inhibiting NP activity. Four dogs given 8-aminoguanosine and deoxyguanosine concurrently for 5 consecutive days showed mean reductions in peripheral blood lymphocytes of 65 +/- 9% range (55-75%) over the test period. Granulocytes, red blood cells, and plateletes remained within the normal range. Administration of 8-aminoguanosine to dogs provides a model of NP deficiency that will permit studies of the specific control of lymphopoiesis and in-vivo immune function. Topics: Animals; Blood Cell Count; Deoxyguanosine; Disease Models, Animal; Dogs; Erythrocytes; Guanosine; Immunologic Deficiency Syndromes; Lymphocytes; Phosphotransferases | 1986 |